During the past decade, The Perth Blood Institute conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 7 clinical trials were completed, i.e. on average, 35% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 4 clinical trials were completed. i.e. 44.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Perth Blood Institute" #1 sponsor was "Baxalta now part of Shire" with 2 trials, followed by "BeiGene" with 2 trials sponsored, "Celgene" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "Rigel Pharmaceuticals" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Perth Blood Institute" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "The Perth Blood Institute" are "Chronic Lymphocytic Leukemia" (4 trials), "Marginal Zone Lymphoma" (4 trials), "Follicular Lymphoma" (3 trials), "Small Lymphocytic Lymphoma" (3 trials) and "Diffuse Large B Cell Lymphoma" (2 trials). Many other conditions were trialed in "The Perth Blood Institute" in a lesser frequency.

Most popular intervention types in "The Perth Blood Institute" are "Drug" (18 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "placebo" (2 trials), "Atezolizumab" (1 trials), "Azacitidine" (1 trials) and "BGB-10188" (1 trials). Other intervention names were less common.

The vast majority of trials in "The Perth Blood Institute" are 20 trials for "All" genders.

Currently, there are NaN active trials in "The Perth Blood Institute". undefined are not yet recruiting, 7 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in The Perth Blood Institute, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in The Perth Blood Institute, 5 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".